Press Releases

 
Press Releases
  Date Title and Summary View
Oct 20, 2016
Cenicriviroc Significantly Improved Fibrosis without Worsening of NASH at One Year SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholi...
Oct 19, 2016
DUBLIN, and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, toda...
Oct 3, 2016
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced upcoming data presentations at the American ...
Sep 20, 2016
DUBLIN and SAN FRANCISCO, Sept. 20, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced th...
Sep 12, 2016
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced the initiation of a Phase 1 study of ce...
Sep 7, 2016
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced that Laurent Fischer, M.D., the company's ...
Sep 1, 2016
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA) today announced that company management will present an overview of the company at the following conferences in September. Rodman & Renshaw 18th Annual Global Investment Conference ...
Aug 9, 2016
-Guest Speaker Arun Sanyal, M.D. to Speak on CENTAUR Study and NASH Landscape- -Conference Call to be Held Today at 4:30 p.m. Eastern Time- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ: TBRA) a clinical-stage biopharmaceutical comp...
Aug 2, 2016
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA) today announced that company management will present an overview of the company at the Canaccord Genuity Growth Conference. Location: Boston Presentation date: Wednesda...
Aug 1, 2016
SOUTH SAN FRANCISCO, Calif., Aug. 1, 2016 (GLOBE NEWSWIRE) -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, will report financial results for the quarter ended June 30, 2016 after market close ...
Page:
1
... NextLast
= add release to Briefcase